<DOC>
	<DOC>NCT00630058</DOC>
	<brief_summary>The purpose of this study is to assess the safety, pharmacokinetics, HCV RNA kinetics, and other viral characteristics after administration of two arms of MP-424 in combination with Peginterferon Alfa 2b (PEG-IFN-a-2b) and Ribavirin (RBV) to patients with chronic hepatitis C.</brief_summary>
	<brief_title>A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Patients diagnosed with genotype 1b chronic hepatitis C Patients diagnosed with decompensated cirrhosis Patients diagnosed with positive HBs antigen in the test</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Protease Inhibitor</keyword>
	<keyword>Telaprevir</keyword>
</DOC>